Operator's Information

Duk-Woo Park, MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. DEFINE-DM Trial: Imaging- and Physiology-Guided State-of-the-Art PCI vs. CABG for DM and Multi-Vessel Disease
  2. Temporal Decoupling Ischemic and Bleeding Risks After Complex PCI; TAILORED-CHIP Trial and Others
  3. Next RCT for DM and Three-Vessel Disease: DEFINE-DM Trial
  4. Post-TAVR Novel Medical Therapy: Role of SGLT2 Inhibitor and ENAVO-TAVR Trial
  5. Contemporary Optimal Antiplatelet Therapy in TAVR: No More Debates?
  6. DM and Three-Vessel Disease: Why We Need New RCTS- DEFINE-DM Trial
  7. State-of-the-art Left Main PCI: What Are the Next?
  8. TAVR in Asia: Optimal TAVR Choice for Asian Patients with Small Annulus, Vessels, and Body Size
  9. Life Time Management: Future Coronary Access
  10. Renal Safety Issues in Dyslipidemia Treatment: Why is it Important?
  11. Escalation and De-Escalation Strategy for CHIP-PCI Patients: The TAILORED-CHIP Trial
  12. DAPT Duration in Complex PCI: Unsettled or Already Established Issues?
  13. PCI Is Enough. - When PCI Should Not Be Standard Treatment
  14. Optimizing Follow-up Strategies Post Complex PCI: Answers from the POST-PCI Trial
  15. Celebration of LM PCI: Joy in Growth, Journeying Towards 25 Years
  16. TAVI Procedure Plan and How to Achieve Successful Results
  17. Make It Simple : TAVR Antithrombotics
  18. Optimal Duration of Antiplatelet Therapy Following Left Main and Bifurcation PCI
  19. FATE-MAIN Trial
  20. TAILRORED-CHIP Trial
  21. Anticoagulation vs. Antiplatelet After TAVR: ADAPT-TAVR Trial
  22. Eagle's Eye View: How to Get Patients on a Statin Timely and Keep Them on It
  23. SAPIEN: Simpler and More Sophisticated (X4 and ALLIANCE)
  24. Insight from All Data of Left Main Revascularization (MAINCOMPARE, SYNTAX, PRECOMBAT, NOBLE, EXCEL)
  25. Edoxaban vs. DAPT for Valve Thrombosis and Cerebral Thromboembolism After TAVR: Deep-Dive into ADAPT-TAVR Trial
  26. Case 1. Left Main Disease
  27. DM and Triple Vessel Disease; Old Evidence and Next New Trials?
  28. My Approach to Left Main Coronary Disease - Master's Skill Secret
  29. LM Revascularization 2022: Guidelines and Concept Change
  30. Long-Term Valve Durability Issues and Optimal Decision-Making: TAVR or SAVR, Mechanical or Bioprosthetic?
  31. Key Message from the ADAPT-TAVR Trial: What We Learned?
  32. Leaflet Thrombosis, Is It Clinically Relevant?
  33. Racial Disparities in TAVR: Similarities and Differences
  34. Clinical Impact of Patient-Prosthesis Mismatch After TAVR
  35. Pragmatic Antithrombotic Strategies According to Bleeding and Ischemic Risk
  36. Two Road Diverged in a Cath Lab: PCI vs CABG in Complex PCI
  37. How to Optimize Sapien 3 Implantation for Future Management: FCA, Bicuspid, ViV, Low risk AS
  38. What Is Your Choice for Adherance Hypertensive Patients with Dyslipidemia?
  39. Escalation and De-Escalation Strategy for CHIP-PCI Patients: The Temporal Tuning in the TAILORED-CHIP Trial
  40. 10-Year Final Report of PRECOMBAT Trial: Deep-Dive
  41. My Challenging LM PCI Case of the Year
  42. East-Asian Paradox for Antithrombotics: Theory, Evidence and Next Strategy
  43. [Master's Keynote Lecture] Hand Down a Secret of Left Main PCI
  44. Antithrombotic and Antiplatelet Choice in Complex PCI
  45. Integrated Use of Imaging and Physiology in Left Main PCI
  46. Optimal Antithrombotics After TAVR
  47. Current Status of TAVR in Korea and US: TP-TAVR Registry
  48. TAVR Will Be a Standard Treatment for All Patients with Aortic Stenosis
  49. Balloon-Expandable SAPIEN 3 Valve
  50. Bifurcation PCI: Data, Evidence, and Guidelines
  51. Impact of Severe Coronary Artery Calcification on PCI Outcomes
  52. Optimal Antithrombotics After TAVR: Ongoing Trials
  53. OCT Versus IVUS for Guiding PCI: Current Evidences and Ongoing OCTIVUS Trial
  54. 10-Year Follow-Up of MAIN-COMPARE Registry and Substudies
  55. Anticoagulation for TAVR: GALILEO, and Yet It Moves.
  56. LM Bifurcation
  57. East-Asian Paradox: How to Optimize P2Y12 Inhibitors for Asians?
  58. How To Do Successful Registry Studies?
  59. Bifurcation PCI 2019: What Are Novel Changes for Technique or Concept?
  60. Highlighting 20 years of CV Protection with Lipitor
  61. PCI in Post-TAVR Patients: Beyond the Barrier
  62. Severe Coronary Calcification: Predictors, Managing Strategy, and Outcomes
  63. Integrated Use of FFR and IVUS in Non-LM Bifurcation PCI
  64. Clinical Impact of Periprocedural Myocardial Injury After TAVR
  65. Optimal Antithrombotic Therapy and Ongoing Clinical Trials
  66. Mainstream of TAVR: Minimalist Approach
  67. Permanent Pacemaker and Para-valvular Leakage: How to Avoid?
  68. Minimalist TAVR with Edwards SAPIEN 3 Valve
  69. Time to Consider Different P2Y12 Strategy for Complex PCI/CHIP Patients: From OPTIMA to TAILORED-PCI Trial
  70. Ture Distal Left Main PCI (Medina 1,1,1 or 1,0,1) Contemporary Strategy: Provisional vs. Complex
  71. Metallic DES Are All Equivalent!
  72. TAVR in Asia: Current Challenges and Future Direction
  73. Comparative Outcomes of Contemporary DES in Real-World: Is There Difference?
  74. EBC-MAIN Like Analysis Using the Largest Real-World Left Main Database
  75. Valve Thrombosis, Durability and Ongoing Antithrombotic Trials for TAVR
  76. OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients
  77. Top 10 Tips on Bifurcation PCI
  78. Heavily Calcified Lesion: Rotational Atherectomy and Others
  79. Keynote Lecture on Bifurcation PCI: Expert's Concept and Technique
  80. TAVR - Moving to Lower Risk: STS or Age Per Se?
  81. Standard vs. Minimalist TAVR: When and How to Change?
  82. [Taped Case] TAVR with Sapien
  83. CTEPH; Diagnosis & Treatment
  84. All Contemporary DES Comparison; Data from Real-World Registry (IRIS-DES)
  85. Trends and Outcomes of Non-LM and LM Bifurcation PCI
  86. How Do I Choose Sapien 3, Evolut R or Lotus in My Practice?
  87. Long-Term Durability Issue of TAVR; Uncertainty or Would Be OK
  88. Contemporary Bifurcation PCI; How Advance over Time?
  89. Generalizability of EXCEL and NOBLE; Comparison with IRIS-MAIN Registry
  90. Where to Go? - Comparative Analysis: BMS, DES vs. BVS / - The Next Step: BVS in Challenging Lesions
  91. Can Different DES Make a Different Outcome?
  92. Future in Transcatheter Heart Valve Treatment
  93. SYNERGY : Latest Experience from Korea
  94. Growing Importance of Evidence in the Management of High CV Risk Patients
  95. How Much Promising BRS in Real-Practice PCI?; Updated Real-World Experience and Registry Data
  96. Bifurcation PCI Summary; Technique or Concept?
  97. BRS in Left Main PCI: Clinical Data and Experience
  98. DES Thrombosis and Restenosis: Still Problematic in Current Real-World with Updated DES
  99. Effect of Statin Therapy on Cardiovascular Outcome in Dyslipidemic Patients with CKD
  100. BVS: They Will Replace Metallic DES?
  101. Comparative Outcomes of New-Generation DES: IRIS-DES
  102. Can BVS Replace the Metal Stent?: Current Status and Future Perspective
  103. Shifting the Paradigm for Lipid Management: Pathways in Achieving Improved ASCVD Outcomes
  104. RDN; Indications & Evidence and Future
  105. Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events after DES Implantation: ASAN-VerifyNow Registry
  106. Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 10-Year Results of Bare-Metal Stents and 5-Year Results of Drug-Eluting Stents From the ASAN–MAIN (ASAN Medical Center–Left MAIN Revascularization) Registry
  107. AMC Experience of the Intervention for the Structural Heart Disease
  108. Early DES - What Did We Learn - Updates from the ZEST Trial
  109. Alternative and Next Antiplatelet Therapy Beyond ADP Blocker
  110. Seeing Is Believing. IVUS Is A Mandatory in All Patients!
  111. DES vs. CABG for Multivessel Disease: Same or Different Interpretation from Registry to RCT
  112. Use of VH-Findings as Surrogate Marker for Anti-Atherosclerotic Drug
  113. Wrapping Up Current Clinical Trials and Future Study Program
  114. VH AMC Clinical Experience
  115. Meta-Analysis of 3,900 Patients with Left Main Disease Intervention (BMS vs DES vs CABG)
  116. Impact of DES on Diabetes Mellitus in Long Coronary Lesion
Conference Slides
Category